印度疫情持续恶化 内地原料药股联邦制药及新华制药曾涨12%-14% 四环医药再探顶
印度昨天新冠确诊病例接近35万人,连续第四天录得超过30万人确诊,屡创全球单日纪录高。有分析指,印度疫情持续恶化,当地原料药厂若因疫情而关闭产能,将有利中国药厂市占率提升。内地原料药股联邦制药(03933.HK)今早曾越牛熊线(6.81元),涨近12%高见7.03元,现造6.76元,回升7.3%,成交急增至1,399万股;新华制药(00719.HK)三连涨,今早曾急涨14%至5.47元,暂受制今年2月所创高位,现造5.14元,续升7.3%,成交急增至376万股。
四环医药(00460.HK)继上周五整固後,今早股价再探顶,最高见3.4元,再创近四年高,现报3.34元,回升7.7%,成交已达1.2亿股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.